Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for Mycosis Fungoides
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Mycosis Fungoides or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on Mycosis Fungoides and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Corneal infiltration and xanthoma formation in mycosisfungoides To report a case of corneal infiltration and xanthoma formation in mycosisfungoides (cutaneous T-cell lymphoma).A middle aged Japanese man with mycosisfungoides (MF) involving the face was referred to Ophthalmology for evaluation of unilateral, painless conjunctival injection. Biopsy of the conjunctiva revealed a malignant T cell population consistent with MF tumor invasion. Years later, he returned following several episodes
Defining the mimics and clinico-histological diagnosis criteria for mycosisfungoides to minimize misdiagnosis Mycosisfungoides (MF) is a significant diagnostic challenge; it has various differential diagnosis especially at an early stage. Our aim was to describe mimics of MF clinically and histologically, and to define significant diagnostic criteria of the disease.This was a retro-prospective cohort of 370 patients in whom the diagnosis of MF was suspected clinically.MF was histologically
Extracorporeal Photopheresis for Sezary Syndrome or MycosisFungoides: Clinical and Cost-Effectiveness Extracorporeal Photopheresis for Sezary Syndrome or MycosisFungoides: Clinical and Cost-Effectiveness | CADTH.ca Find the information you need Extracorporeal Photopheresis for Sezary Syndrome or MycosisFungoides: Clinical and Cost-Effectiveness Extracorporeal Photopheresis for Sezary Syndrome or MycosisFungoides: Clinical and Cost-Effectiveness Published on: September 30, 2015 Project (...) Number: RB0915-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of extracorporeal photopheresis (ECP) for the management of Sezary Syndrome or Mycosisfungoides? What is the cost-effectiveness of ECP for the management of Sezary Syndrome or Mycosisfungoides? Key Message One systematic review, four non-randomized studies, and one economic evaluation were identified regarding extracorporeal
Phototherapy for early-stage mycosisfungoides Phototherapy for early-stage mycosisfungoides Phototherapy for early-stage mycosisfungoides Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Phototherapy for early-stage mycosisfungoides. Lansdale: HAYES, Inc.. Healthcare Technology Brief Publication Dates. 2012 Authors' conclusions Cutaneous T-cell lymphomas (...) (CTCL) are a heterogeneous group of non-Hodgkin's lymphomas characterized by their initial manifestation in the skin. Mycosisfungoides (MF), which evolves from scaly skin patches and plaques, is the most common form of CTCL affecting approximately 65% of cases. The incidence of MF in the United States has been estimated at 6 cases per 1 million individuals with a male predominance. MF is broadly divided into early- and advanced-stage disease and classified into four clinical stages (I-IV). Skin
Mycosisfungoides and Sézary syndrome. Mycosisfungoides and Sézary syndrome are the most common of the cutaneous T-cell lymphomas, which are a heterogeneous group of neoplasms that affect the skin as a primary site. Although the aetiologies of mycosisfungoides and Sézary syndrome are unknown, important insights have been gained in the immunological and genetic perturbations that are associated with these diseases. Unlike some B-cell lymphomas, cutaneous T-cell lymphomas as a group are rarely (...) increasing toxic effects in advanced disease that is otherwise difficult to treat. Although present treatment strategies are generally not curative, there is hope that experimental treatments, particularly immunotherapy, might eventually reverse or suppress the abnormalities of mycosisfungoides and Sézary syndrome to the point at which they become non-life-threatening, chronic diseases.
EORTC consensus recommendations for the treatment of mycosisfungoides/Sézary syndrome Guidelines entitled: “EORTC consensus recommendations for the treatment of mycosisfungoides/Sézary syndrome” developed by the Guideline Subcommittee of the European Dermatology Forum Subcommittee Members: Prof. Dr. F. Trautinger, Vienna (Austria) Prof. Dr. R. Knobler, Viena (Austria) Prof. Dr. R. Willemze, Leiden (The Netherlands) Prof. Dr. K. Peris, L'Aquila (Italy) Prof. Dr. R. Stadler, Minden (Germany (...) . Dr. P. Ortiz Romero no conflict declared Prof. Dr. A. Ranki no conflict declared Prof. Dr. K. Peris no conflict declared Prof. Dr. M. D’Incan no conflict declared Prof. Dr. S. Whittaker no conflict declared Prof. Dr. L. Laroche no answer Page 1 of 53 EORTC consensus recommendations for the treatment of mycosisfungoides/Sézary syndrome Authors: Franz Trautinger 1 , Robert Knobler* 1 , Rein Willemze 2 , Ketty Peris 3 , Rudolph Stadler 4 , Liliane Laroche 5 , Michel D’Incan 6 , Annamari Ranki 7
Systemic therapy of cutaneous T-cell lymphomas (mycosisfungoides and the Sezary syndrome) Systemic therapy of cutaneous T-cell lymphomas (mycosisfungoides and the Sezary syndrome) Systemic therapy of cutaneous T-cell lymphomas (mycosisfungoides and the Sezary syndrome) Bunn P A, Hoffman S J, Norris D, Golitz L E, Aeling J L Authors' objectives To review recent studies of systemic therapy for mycosisfungoides and the Sezary syndrome. Searching MEDLINE was searched from 1988 to 1994 (...) . Participants included in the review Patients with mycosisfungoides or the Sezary syndrome. Outcomes assessed in the review The objective response to treatment (complete response or partial response) was assessed. How were decisions on the relevance of primary studies made? The authors do not state how the papers were selected for the review, or how many of the authors performed the selection. Assessment of study quality The authors do not state that they assessed validity. Data extraction The data were
A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosisfungoides. Mycosisfungoides is a T-cell lymphoma that arises in the skin and progresses at highly variable rates. Nonradomized studies have suggested that early aggressive therapy may improve the prognosis in this usually fatal disease. We studied 103 patients with mycosisfungoides, who, after complete staging, were randomly assigned to receive either (...) leukemia. Patients receiving combined therapy had a significantly higher rate of complete response, documented by biopsy, than patients receiving conservative therapy (38 percent vs. 18 percent; P = 0.032). After a median follow-up of 75 months, however, there was no significant difference between the treatment groups in disease-free or overall survival. We conclude that early aggressive therapy with radiation and chemotherapy does not improve the prognosis for patients with mycosisfungoides